16 Jun 2016
Prelims in line, DEV610 confirmed as generic Advair
FY16 prelims look in line/slightly ahead with a PBT / EPS beat down to lower Depreciation and lower tax than guided. Net Debt was £97.0m. The outlook positive with a number of potentially significant product launches slated for this year, including DEV610, which will likely require significant stock built ahead of launch. No material changes to forecasts expected at this stage, but momentum is building and there is the potential for "material outperformance" later in the year dependent on succes ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Prelims in line, DEV610 confirmed as generic Advair
FY16 prelims look in line/slightly ahead with a PBT / EPS beat down to lower Depreciation and lower tax than guided. Net Debt was £97.0m. The outlook positive with a number of potentially significant product launches slated for this year, including DEV610, which will likely require significant stock built ahead of launch. No material changes to forecasts expected at this stage, but momentum is building and there is the potential for "material outperformance" later in the year dependent on succes ....